Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients

Zehir, Ahmet, Benayed, Ryma, Shah, Ronak H, Syed, Aijazuddin, Middha, Sumit, Kim, Hyunjae R, Srinivasan, Preethi, Gao, Jianjiong +92 more·2017·Nature Medicine
DOI 10.1038/nm.4333

Cited by (1,010)

Items 101–200 of 1,010

  1. Reliable Pan-Cancer Microsatellite Instability Assessment by Using Targeted Next-Generation Sequencing Data
    Sumit Middha, Liying Zhang, Khédoudja Nafa, Gowtham Jayakumaran, Donna Wong, Hyunjae Ryan Kim, Justyna Sadowska, Michael F. Berger, Deborah F. DeLair, Jinru Shia et al. · 2017 · JCO Precision Oncology
  2. Feasibility and utility of a panel testing for 114 cancer‐associated genes in a clinical setting: A hospital‐based study
    Kuniko Sunami, Hitoshi Ichikawa, Takashi Kubo, Mamoru Kato, Yutaka Fujiwara, Akihiko Shimomura, Takafumi Koyama, Hiroki Kakishima, Mayuko Kitami, Hiromichi Matsushita et al. · 2019 · Cancer Science
  3. Genetic Predictors of Response to Systemic Therapy in Esophagogastric Cancer
    Yelena Yuriy Janjigian, Francisco Sánchez-Vega, Philip Jonsson, Walid Khaled Chatila, Jaclyn Frances Hechtman, Geoffrey Yuyat Ku, Jamie Cathleen Riches, Yaelle Tuvy, Ritika Kundra, Nancy Bouvier et al. · 2017 · Cancer Discovery
  4. KRAS Alleles: The Devil Is in the Detail
    Haigis, Kevin M. · 2017 · Trends in Cancer
  5. ESMO recommendations on the standard methods to detect NTRK fusions in daily practice and clinical research
    Caterina Marchiò, Maurizio Scaltriti, Marc Ladanyi, Anthony John Iafrate, Frédéric Bibeau, Manfred Dietel, Jaclyn Frances Hechtman, Teresa Troiani, Fernando López‐Ríos, J.-Y. Douillard et al. · 2019 · Annals of Oncology
  6. The molecular biology of pancreatic adenocarcinoma: Translational challenges and clinical perspectives
    Wang, Shun, Zheng, Yan, Yang, Feng, Zhu, Le, Zhu, Xiao-Qiang, Wang, Zhe-Fang, Wu, Xiao-Lin, Zhou, Cheng-Hui, Yan, Jia-Yan, Hu, Bei-Yuan et al. · 2021 · Signal Transduction and Targeted Therapy
  7. Clinical applications of artificial intelligence and machine learning in cancer diagnosis: looking into the future
    Muhammad Javed Iqbal, Zeeshan Javed, Haleema Sadia, Ijaz A. Qureshi, Asma Irshad, Rais Ahmed, Kausar A. Malik, Shahid Raza, Asif Abbas, Raffaele Pezzani et al. · 2021 · Cancer Cell International
  8. Multimodal data integration using machine learning improves risk stratification of high-grade serous ovarian cancer
    Boehm, Kevin M., Aherne, Emily A., Ellenson, Lora, Nikolovski, Ines, Alghamdi, Mohammed, Vázquez-García, Ignacio, Zamarin, Dmitriy, Long Roche, Kara, Liu, Ying, Patel, Druv et al. · 2022 · Nature Cancer
  9. First-line pembrolizumab and trastuzumab in HER2-positive oesophageal, gastric, or gastro-oesophageal junction cancer: an open-label, single-arm, phase 2 trial
    Yelena Yuriy Janjigian, Steven Brad Maron, Walid Khaled Chatila, Brittanie M Millang, Shweta S. Chavan, Carly Alterman, Joanne F. Chou, Michal Fani Segal, Marc Z. Simmons, Parisa Momtaz et al. · 2020 · The Lancet Oncology
  10. Fibroblast growth factor receptors as treatment targets in clinical oncology
    Masaru Katoh · 2018 · Nature Reviews Clinical Oncology
  11. BRAF Inhibition in BRAF V600 -Mutant Gliomas: Results From the VE-BASKET Study
    Thomas Joseph Kaley, Mehdi Touat, Vivek Subbiah, Antoine Hollebecque, Jordi Ahnert Rodon, Albert Craig Lockhart, Vicki Leigh Keedy, Franck Bielle, Ralf‐Dieter Hofheinz, Florence Joly et al. · 2018 · Journal of Clinical Oncology
  12. Targeting p53 for the treatment of cancer
    Michael Joe Duffy, Naoise C. Synnott, Shane O’Grady, John Paul Crown · 2020 · Seminars in Cancer Biology
  13. Tumor origin detection with tissue-specific miRNA and DNA methylation markers
    Wei Tang, Shixiang Wan, Zhen Yang, Andrew Erich Teschendorff, Quan Zou · 2017 · Bioinformatics
  14. Implementing TMB measurement in clinical practice: considerations on assay requirements
    Reinhard Büttner, John W. Longshore, Fernando López‐Ríos, Sabine Merkelbach‐Bruse, Nicola Normanno, Étienne Rouleau, Frederique Madeleine Penault-Llorca · 2019 · ESMO Open
  15. Targeting an RNA-Binding Protein Network in Acute Myeloid Leukemia
    Wang, Eric, Lu, Sydney X., Pastore, Alessandro, Chen, Xufeng, Imig, Jochen, Chun-Wei Lee, Stanley, Hockemeyer, Kathryn, Ghebrechristos, Yohana E., Yoshimi, Akihide, Inoue, Daichi et al. · 2019 · Cancer Cell
  16. Tumor Mutation Burden and Efficacy of EGFR-Tyrosine Kinase Inhibitors in Patients with EGFR -Mutant Lung Cancers
    Michael David Offin, Hira A. Rizvi, Megan Tenet, Ai Ni, Francisco Sánchez-Vega, Bob T. Li, Alexander Edward Dela Cruz Drilon, Mark G. Kris, Charles M. Rudin, Nikolaus D. Schultz et al. · 2018 · Clinical Cancer Research
  17. Fusions in solid tumours: diagnostic strategies, targeted therapy, and acquired resistance
    Alison M. Schram, Matthew T. Chang, Philip Jonsson, Alexander Edward Dela Cruz Drilon · 2017 · Nature Reviews Clinical Oncology
  18. Ovarian cancer mutational processes drive site-specific immune evasion
    Ignacio Vázquez-Garćıa, Florian Uhlitz, Nicholas Ceglia, Jamie L. Lim, Michelle Ka Yan Wu, Neeman Mohibullah, Juliana Niyazov, Arvin Eric B. Ruiz, Kevin Michael Boehm, Viktoria Bojilova et al. · 2022 · Nature
  19. A targetable LIFR−NF-κB−LCN2 axis controls liver tumorigenesis and vulnerability to ferroptosis
    Fan Yao, Yalan Deng, Yang Zhao, Ying Mei, Yilei Zhang, Xiaoguang Liu, Consuelo Martinez, Xiaohua Su, Roberto R. Rosato, Hongqi Teng et al. · 2021 · Nature Communications
  20. SMARCA4-Deficient Thoracic Sarcomatoid Tumors Represent Primarily Smoking-Related Undifferentiated Carcinomas Rather Than Primary Thoracic Sarcomas
    Natasha Rekhtman, Joseph Montecalvo, Jason C. Chang, Deepu Alex, Ryan N. Ptashkin, Ni Ai, Jennifer L. Sauter, Brie E. Kezlarian, Achim A. Jungbluth, Patrice Desmeules et al. · 2019 · Journal of Thoracic Oncology
  21. SHP2 inhibition prevents adaptive resistance to MEK inhibitors in multiple cancer models
    Fedele, Carmine, Ran, Hao, Diskin, Brian, Wei, Wei, Jen, Jayu, Geer, Mitchell J., Araki, Kiyomi, Ozerdem, Ugur, Simeone, Diane M., Miller, George et al. · 2018 · Cancer Discovery
  22. Clinical and molecular correlates of PD-L1 expression in patients with lung adenocarcinomas
    A.J. Schoenfeld, H. Rizvi, Chai Bandlamudi, Jennifer L. Sauter, William David Travis, Natasha Rekhtman, Andrew J. Plodkowski, Rocío Pérez-Johnston, Peter Sawan, Amanda Beras et al. · 2020 · Annals of Oncology
  23. Combination of TMB and CNA Stratifies Prognostic and Predictive Responses to Immunotherapy Across Metastatic Cancer
    Li Liu, Xue Bai, Jian Wang, Xin-Ran Tang, Dehua Wu, Shasha Du, Xiuju Du, Yaowei Zhang, Hongbo Zhu, Yuan Fang et al. · 2019 · Clinical Cancer Research
  24. PD-L1 expression, tumor mutational burden, and response to immunotherapy in patients with MET exon 14 altered lung cancers
    Joshua K. Sabari, Giulia Costanza Leonardi, Catherine A. Shu, Renato Umeton, Joseph Montecalvo, Ai Ni, R. Chen, Jordan Dienstag, Chebli Mrad, Isabella Bergagnini et al. · 2018 · Annals of Oncology
  25. NRF2 as a regulator of cell metabolism and inflammation in cancer
    Feng He, Laura Antonucci, Michael Karin · 2020 · Carcinogenesis
  26. First-in-Human Phase I/IB Dose-Finding Study of Adagrasib (MRTX849) in Patients With Advanced <i>KRAS</i> <sup> <i>G12C</i> </sup> Solid Tumors (KRYSTAL-1)
    Ou, Sai-Hong Ignatius, Jänne, Pasi A., Leal, Ticiana A., Rybkin, Igor I., Sabari, Joshua K., Barve, Minal A., Bazhenova, Lyudmila, Johnson, Melissa L., Velastegui, Karen L., Cilliers, Cornelius et al. · 2022 · Journal of Clinical Oncology
  27. GA4GH: International policies and standards for data sharing across genomic research and healthcare
    Heidi L. Rehm, Angela J.H. Page, Lindsay Smith, Jeremy B. Adams, Gil Alterovitz, Lawrence J. Babb, Maxmillian P. Barkley, Michael Baudis, Michael J. S. Beauvais, Tim Beck et al. · 2021 · Cell Genomics
  28. Detecting the mutational signature of homologous recombination deficiency in clinical samples
    D. Gulhan, Jake June-Koo Lee, Giorgio E. M. Melloni, Isidro Cortés‐Ciriano, Peter J. Park · 2019 · Nature Genetics
  29. Tumor mutational burden quantification from targeted gene panels: major advancements and challenges
    Laura Fancello, Sara Gandini, Pier Giuseppe Pelicci, Luca Mazzarella · 2019 · Journal for ImmunoTherapy of Cancer
  30. Dabrafenib and Trametinib in Patients With Tumors With BRAF V600E Mutations: Results of the NCI-MATCH Trial Subprotocol H
    April K.S. Salama, Shuli Li, Erin Renee Macrae, Jong‐In Park, Edith Peterson Mitchell, James A. Zwiebel, Helen X. Chen, Robert J. Gray, Lisa M. McShane, Larry Rubinstein et al. · 2020 · Journal of Clinical Oncology
  31. Evolutionary divergence of HLA class I genotype impacts efficacy of cancer immunotherapy
    Diego Chowell, Chirag Krishna, Federica Pierini, Vladimir Makarov, Naiyer A. Rizvi, Fengshen Kuo, Luc G.T. Morris, Nadeem Riaz, Tobias L. Lenz, Timothy An-thy Chan · 2019 · Nature Medicine
  32. Pan-cancer circulating tumor DNA detection in over 10,000 Chinese patients
    Yongliang Zhang, Yu Yao, Yaping Xu, Lifeng Li, Yan Gong, Kai Zhang, Meng Zhang, Yanfang Guan, Lianpeng Chang, Xuefeng Xia et al. · 2021 · Nature Communications
  33. Immunogenomic profiling determines responses to combined PARP and PD-1 inhibition in ovarian cancer
    Anniina Färkkilä, D. Gulhan, Julia Casado, Connor A. Jacobson, Huy Q. Nguyen, Bose S. Kochupurakkal, Zoltan Maliga, Clarence Yapp, Yu‐An Chen, Denis Schapiro et al. · 2020 · Nature Communications
  34. Molecular subtyping and genomic profiling expand precision medicine in refractory metastatic triple-negative breast cancer: the FUTURE trial
    Yi-Zhou Jiang, Yin Liu, Yi Xiao, Xin Hu, Lin Jiang, Wen‐Jia Zuo, Ding Ma, Jia-Han Ding, Xiaoyu Zhu, Jianjun Zou et al. · 2020 · Cell Research
  35. TRK inhibitors in TRK fusion-positive cancers
    Alexander Edward Dela Cruz Drilon · 2019 · Annals of Oncology
  36. Molecular Landscape and Actionable Alterations in a Genomically Guided Cancer Clinical Trial: National Cancer Institute Molecular Analysis for Therapy Choice (NCI-MATCH)
    Flaherty, Keith T., Gray, Robert J., Chen, Alice P., Li, Shuli, McShane, Lisa M., Patton, David, Hamilton, Stanley R., Williams, P. Mickey, Iafrate, A. John, Sklar, Jeffrey et al. · 2020 · Journal of Clinical Oncology
  37. Pan-cancer whole-genome comparison of primary and metastatic solid tumours
    Francisco Martínez-Jiménez, Ali Movasati, Sascha R. Brunner, Luan Nguyen, Peter Priestley, Edwin P. J. G. Cuppen, Arne van Hoeck · 2023 · Nature
  38. Double PIK3CA mutations in cis increase oncogenicity and sensitivity to PI3Kα inhibitors
    Neil Vasan, Pedram Razavi, Jared Lee Johnson, Hong Shao, Hardik Shah, Alesia Antoine, Erik Ladewig, Alexander N. Gorelick, Ting-Yu Lin, Eneda Toska et al. · 2019 · Science
  39. The Promises and Challenges of Tumor Mutation Burden as an Immunotherapy Biomarker: A Perspective from the International Association for the Study of Lung Cancer Pathology Committee
    Lynette Marie Sholl, Fred R. Hirsch, David M. Hwang, Johan Botling, Fernando López‐Ríos, Lukas Bubendorf, Mari A. Mino-Kenudson, Anja Christiane Roden, Mary Beth Beasley, Alain Borczuk et al. · 2020 · Journal of Thoracic Oncology
  40. Distinct structural classes of activating FOXA1 alterations in advanced prostate cancer
    Parolia, Abhijit, Cieslik, Marcin, Chu, Shih-Chun, Xiao, Lanbo, Ouchi, Takahiro, Zhang, Yuping, Wang, Xiaoju, Vats, Pankaj, Cao, Xuhong, Pitchiaya, Sethuramasundaram et al. · 2019 · Nature
  41. Tumor copy number alteration burden is a pan-cancer prognostic factor associated with recurrence and death
    Haley Hieronymus, Rajmohan Murali, Amy L. Tin, Kamlesh Kumar Yadav, Wassim M. Abida, Henrik Møller, Daniel Maurice Berney, Howard I. Scher, Brett Stewart Carver, Peter T. Scardino et al. · 2018 · eLife
  42. Somatic Genomic Testing in Patients With Metastatic or Advanced Cancer: ASCO Provisional Clinical Opinion
    Debyani Chakravarty, Amber Johnson, Jeffrey Sklar, Neal Ian Lindeman, Kathleen N. Moore, Shridar Ganesan, Christine Marie Lovly, Jane Perlmutter, Stacy W. Gray, Jimmy Hwang et al. · 2022 · Journal of Clinical Oncology
  43. Acquired resistance to IDH inhibition through trans or cis dimer-interface mutations
    Intlekofer, Andrew M., Shih, Alan H., Wang, Bo, Nazir, Abbas, Rustenburg, Ariën S., Albanese, Steven K., Patel, Minal, Famulare, Christopher, Correa, Fabian M., Takemoto, Naofumi et al. · 2018 · Nature
  44. Therapeutic Targeting of RNA Splicing Catalysis through Inhibition of Protein Arginine Methylation
    Jia Yi Fong, Luca Pignata, Pierre-Alexis Vincent Goy, Kimihito Cojin Kawabata, Stanley Chun-Wei Lee, Cheryl M. Koh, Daniele Musiani, Enrico Massignani, Andriana G. Kotini, Alex Penson et al. · 2019 · Cancer Cell
  45. The Angiosarcoma Project: enabling genomic and clinical discoveries in a rare cancer through patient-partnered research
    Corrie Painter, Esha Jain, Brett N. Tomson, Michael Dunphy, Rachel E. Stoddard, Beena S. Thomas, Alyssa L. Damon, Shahrayz Shah, Dewey Kim, Jorge Gómez Tejeda Zañudo et al. · 2020 · Nature Medicine
  46. Frameshift events predict anti-PD-1/L1 response in head and neck cancer.
    G. Hanna, P. Lizotte, Megan E. Cavanaugh, Frank C. Kuo, Priyanka Shivdasani, Alexander Frieden, N. Chau, J. Schoenfeld, J. Lorch, R. Uppaluri et al. · 2018 · JCI Insight
  47. Concurrent Alterations in EGFR-Mutant Lung Cancers Associated with Resistance to EGFR Kinase Inhibitors and Characterization of MTOR as a Mediator of Resistance
    Yu, Helena A., Suzawa, Ken, Jordan, Emmet, Zehir, Ahmet, Ni, Ai, Kim, Ryan, Kris, Mark G., Hellmann, Matthew D., Li, Bob T., Somwar, Romel et al. · 2018 · Clinical Cancer Research
  48. Clonal Relatedness and Mutational Differences between Upper Tract and Bladder Urothelial Carcinoma
    François Audenet, Sumit Isharwal, Eugene K. Cha, Mark T.A. Donoghue, Esther N Drill, Irina Ostrovnaya, Eugene J. Pietzak, John P. Sfakianos, Aditya Bagrodia, Paari J Murugan et al. · 2018 · Clinical Cancer Research
  49. Targeting the PI3K/AKT/mTOR and RAF/MEK/ERK pathways for cancer therapy
    Qingfang Li, Zhihui Li, Ting L. Luo, Shi H · 2022 · Molecular Biomedicine
  50. Tumor Mutation Burden as a Biomarker in Resected Non–Small-Cell Lung Cancer
    Siddhartha H. K. Devarakonda, Federico Rotolo, Ming‐Sound Tsao, Irena Lanc, Elisabeth M. Brambilla, Ashiq Masood, Ken André Olaussen, Robert S. Fulton, Shingo Sakashita, Anne Mc Leer et al. · 2018 · Journal of Clinical Oncology
  51. Identifying patients with NTRK fusion cancer
    James P. Solomon, Ryma Benayed, Jaclyn Frances Hechtman, Marc Ladanyi · 2019 · Annals of Oncology
  52. SHP2 inhibition diminishes KRASG12C cycling and promotes tumor microenvironment remodeling
    Fedele, Carmine, Li, Shuai, Teng, Kai Wen, Foster, Connor J.R., Peng, David, Ran, Hao, Mita, Paolo, Geer, Mitchell J., Hattori, Takamitsu, Koide, Akiko et al. · 2021 · Journal of Experimental Medicine
  53. Improved prediction of immune checkpoint blockade efficacy across multiple cancer types
    Diego Chowell, Seong‐Keun Yoo, Cristina Valero, Alessandro Pastore, Chirag Krishna, Mark Lee, Douglas Robert Hoen, Hongyu Shi, Daniel W. Kelly, Neal Patel et al. · 2021 · Nature Biotechnology
  54. Current therapy and drug resistance in metastatic castration-resistant prostate cancer
    Maoping Cai, Xian‐Lu Song, Xinan Li, Mingkun Chen, Jiading Guo, Dong‐Hua Yang, Zhanghui Chen, Shan‐Chao Zhao · 2023 · Drug Resistance Updates
  55. Current Trends and Future Prospects of Molecular Targeted Therapy in Head and Neck Squamous Cell Carcinoma
    Naoya Kitamura, Shinya Sento, Yasumasa Yoshizawa, Eri Sasabe, Yasusei Kudo, Tetsuya Yamamoto · 2020 · International Journal of Molecular Sciences
  56. Big data in basic and translational cancer research
    Jiang, Peng, Sinha, Sanju, Aldape, Kenneth, Hannenhalli, Sridhar, Sahinalp, Cenk, Ruppin, Eytan · 2022 · Nature Reviews Cancer
  57. Mechanisms of metastatic colorectal cancer
    Adrià Cañellas-Socias, Elena Sancho, Eduard Batlle · 2024 · Nature Reviews Gastroenterology & Hepatology
  58. Translational advances in pancreatic ductal adenocarcinoma therapy
    Abdel Nasser Hosein, Stephanie K. Dougan, Andrew J. Aguirre, Anirban Maitra · 2022 · Nature Cancer
  59. Pan-cancer analysis of bi-allelic alterations in homologous recombination DNA repair genes
    Nadeem Riaz, Pedro Blecua, Raymond S. Lim, Ronglai Shen, Daniel S. Higginson, Nils Weinhold, Larry Norton, Britta Weigelt, Simon N. Powell, Jorge Sergio Reis-Filho · 2017 · Nature Communications
  60. Somatic HLA Class I Loss Is a Widespread Mechanism of Immune Evasion Which Refines the Use of Tumor Mutational Burden as a Biomarker of Checkpoint Inhibitor Response
    Meagan Montesion, Karthikeyan Murugesan, Dexter X. Jin, Radwa Sharaf, Nora Sánchez, Ameet Guria, Max Minker, Gerald Li, Virginia A. Fisher, Ethan S. Sokol et al. · 2020 · Cancer Discovery
  61. The association between tumor mutational burden and prognosis is dependent on treatment context
    Cristina Valero, Mark Andrew Lee, Douglas Robert Hoen, Jingming Wang, Zaineb Nadeem, Neal Patel, Michael Andrew Postow, Alexander Noor Shoushtari, George Plitas, Vinod P. Balachandran et al. · 2021 · Nature Genetics
  62. Concurrent Mutations in STK11 and KEAP1 Promote Ferroptosis Protection and SCD1 Dependence in Lung Cancer
    Corrin A. Wohlhieter, Allison L. Richards, Fathema Z. Uddin, Christopher H. Hulton, Àlvaro Quintanal-Villalonga, Axel S. Martin, Elisa de Stanchina, Umesh Kumar Bhanot, Marina Asher, Nisargbhai Shah et al. · 2020 · Cell Reports
  63. Arsenic Trioxide Rescues Structural p53 Mutations through a Cryptic Allosteric Site
    Shuo Chen, Jiale Wu, Ying Liang, Yigang Tang, Huaxin Song, Lili Wu, Yangfei Xing, Ni Yan, Yuntong Li, Zhengyuan Wang et al. · 2020 · Cancer Cell
  64. The management of metastatic GIST: current standard and investigational therapeutics
    Ciara Marie Kelly, Laura Gutiérrez Sainz, Ping Chi · 2021 · Journal of Hematology & Oncology
  65. Clinical validation of the tempus xT next-generation targeted oncology sequencing assay
    Nike T. Beaubier, Robert W. Tell, Denise Lau, Jerod Parsons, Stephen Bush, Jason F. Perera, Shelly Sorrells, Timothy Baker, Alan Lee Chang, Jackson Michuda et al. · 2019 · Oncotarget
  66. ATM inhibition enhances cancer immunotherapy by promoting mtDNA leakage and cGAS/STING activation
    Mengjie Hu, Min Zhou, Xuhui Bao, Dong Pan, Meng Jiao, Xinjian Liu, Fang Li, Chuan‐Yuan Li · 2020 · Journal of Clinical Investigation
  67. Germline-focussed analysis of tumour-only sequencing: recommendations from the ESMO Precision Medicine Working Group
    Diana L. Mandelker, Mark T.A. Donoghue, Sabrina Talukdar, Chaitanya Bandlamudi, Preethi Srinivasan, Malavika Vivek, S. Jezdic, Helen Hanson, Katie M.G. Snape, Anju Kulkarni et al. · 2019 · Annals of Oncology
  68. Tumor mutational burden standardization initiatives: Recommendations for consistent tumor mutational burden assessment in clinical samples to guide immunotherapy treatment decisions
    Albrecht Stenzinger, Jeffrey D. Allen, J. Maas, Mark D. Stewart, Diana M. Merino, Madison M. Wempe, Manfred Dietel · 2019 · Genes Chromosomes and Cancer
  69. Multi‑layered prevention and treatment of chronic inflammation, organ fibrosis and cancer associated with canonical WNT/β‑catenin signaling activation (Review)
    Masaru Katoh · 2018 · International Journal of Molecular Medicine
  70. Genomic Methods Identify Homologous Recombination Deficiency in Pancreas Adenocarcinoma and Optimize Treatment Selection
    Wungki Park, Jiapeng Chen, Joanne F. Chou, Anna M. Varghese, Kenneth H. Yu, Winston Wong, Marinela Capanu, Vinod P. Balachandran, Caitlin A. McIntyre, Imane El Dika et al. · 2020 · Clinical Cancer Research
  71. Towards individualized therapy for metastatic renal cell carcinoma
    Ritesh R. Kotecha, Robert John Motzer, Martin Henner Voss · 2019 · Nature Reviews Clinical Oncology
  72. Tracing Oncogene Rearrangements in the Mutational History of Lung Adenocarcinoma
    Lee, Jake June-Koo, Park, Seongyeol, Park, Hansol, Kim, Sehui, Lee, Jongkeun, Lee, Junehawk, Youk, Jeonghwan, Yi, Kijong, An, Yohan, Park, In Kyu et al. · 2019 · Cell
  73. Acquired HER2 mutations in ER+ metastatic breast cancer confer resistance to estrogen receptor–directed therapies
    Utthara Nayar, Ofir Cohen, Christian Kapstad, Michael S. Cuoco, Adrienne Gropper Waks, Seth Andrew Wander, Corrie Painter, Samuel S. Freeman, Nicole S. Persky, Lori Marini et al. · 2018 · Nature Genetics
  74. Randomized trials and endpoints in advanced HCC: Role of PFS as a surrogate of survival
    Josep M. Llovet, Robert Montal, Augusto Villanueva · 2019 · Journal of Hepatology
  75. The landscape of selection in 551 esophageal adenocarcinomas defines genomic biomarkers for the clinic
    Alexander M. Frankell, Sriganesh Jammula, Xiaodun Li, Gianmarco Contino, Sarah Killcoyne, Sujath Abbas, Juliane Perner, Lawrence Bower, Ginny Devonshire, Emma Ococks et al. · 2019 · Nature Genetics
  76. Clinical sequencing of soft tissue and bone sarcomas delineates diverse genomic landscapes and potential therapeutic targets
    Nacev, Benjamin A., Sanchez-Vega, Francisco, Smith, Shaleigh A., Antonescu, Cristina R., Rosenbaum, Evan, Shi, Hongyu, Tang, Cerise, Socci, Nicholas D., Rana, Satshil, Gularte-Mérida, Rodrigo et al. · 2022 · Nature Communications
  77. Preclinical and clinical development of neoantigen vaccines
    L. Li, Simon Peter Goedegebuure, William E. Gillanders · 2017 · Annals of Oncology
  78. Integration of Genomic and Transcriptional Features in Pancreatic Cancer Reveals Increased Cell Cycle Progression in Metastases
    Ashton Anthony Connor, Robert Edward Denroche, Gun Ho Jang, Mathieu Lemire, Amy Xin Wei Zhang, Michelle Chan‐Seng‐Yue, Gavin W. Wilson, Robert C. Grant, Daniele Merico, Ilinca M. Lungu et al. · 2019 · Cancer Cell
  79. 9p21 loss confers a cold tumor immune microenvironment and primary resistance to immune checkpoint therapy
    Guangchun Han, Guoliang Yang, Dapeng Hao, Yang Lü, Kyaw Zin Thein, Benjamin Scott S Simpson, Jianfeng Chen, Ryan Sun, Omar Alhalabi, Ruiping Wang et al. · 2021 · Nature Communications
  80. Targeting KRAS mutant cancers: from druggable therapy to drug resistance
    Zhu, Chunxiao, Guan, Xiaoqing, Zhang, Xinuo, Luan, Xin, Song, Zhengbo, Cheng, Xiangdong, Zhang, Weidong, Qin, Jiang-Jiang · 2022 · Molecular Cancer
  81. Clinical cancer genomic profiling
    Debyani Chakravarty, David B. Solit · 2021 · Nature Reviews Genetics
  82. Sequence determinants of human gene regulatory elements
    Sahu, Biswajyoti, Hartonen, Tuomo, Pihlajamaa, Päivi, Wei, Bei, Dave, Kashyap, Zhu, Fangjie, Kaasinen, Eevi, Lidschreiber, Katja, Lidschreiber, Michael, Daub, Carsten O. et al. · 2022 · Nature Genetics
  83. 5-Fluorouracil treatment induces characteristic T>G mutations in human cancer
    2019
  84. Prospective Evaluation of Germline Alterations in Patients With Exocrine Pancreatic Neoplasms
    Lowery, Maeve A, Wong, Winston, Jordan, Emmet J, Lee, Jonathan W, Kemel, Yelena, Vijai, Joseph, Mandelker, Diana, Zehir, Ahmet, Capanu, Marinela, Salo-Mullen, Erin et al. · 2018 · JNCI: Journal of the National Cancer Institute
  85. Isoform Switching as a Mechanism of Acquired Resistance to Mutant Isocitrate Dehydrogenase Inhibition
    James J. Harding, Maeve Aine Lowery, Alan H. Shih, Juan M. Schvartzman, Shengqi Hou, Christopher A. Famulare, Minal A. Patel, Mikhail Roshal, Richard K. G. Do, Ahmet Zehir et al. · 2018 · Cancer Discovery
  86. Detection of Tumor NTRK Gene Fusions to Identify Patients Who May Benefit from Tyrosine Kinase (TRK) Inhibitor Therapy
    Susan Jean Hsiao, Ahmet Zehir, Anthony N. Sireci, Dara L. Aisner · 2019 · Journal of Molecular Diagnostics
  87. The Molecular Analysis for Therapy Choice (NCI-MATCH) Trial: Lessons for Genomic Trial Design
    Keith T. Flaherty, Robert J. Gray, Alice P. Chen, Shuli Li, David R. Patton, Stanley R. Hamilton, Paul Mickey Williams, Edith Peterson Mitchell, Anthony John Iafrate, Jeffrey Sklar et al. · 2020 · JNCI Journal of the National Cancer Institute
  88. Mutations in BRCA1 and BRCA2 differentially affect the tumor microenvironment and response to checkpoint blockade immunotherapy
    Samstein, Robert M., Krishna, Chirag, Ma, Xiaoxiao, Pei, Xin, Lee, Ken-Wing, Makarov, Vladimir, Kuo, Fengshen, Chung, Jonathan, Srivastava, Raghvendra M., Purohit, Tanaya A. et al. · 2020 · Nature Cancer
  89. Clinicopathologic Features of Non–Small-Cell Lung Cancer Harboring an NTRK Gene Fusion
    Anna F. Farago, Martin S. Taylor, Robert Charles Doebele, Viola Weijia Zhu, Shivaani Kummar, Alexander I. Spira, Theresa A. Boyle, Eric B. Haura, Maria E. Arcila, Ryma Benayed et al. · 2018 · JCO Precision Oncology
  90. Microsatellite instability in gastric cancer: molecular bases, clinical perspectives, and new treatment approaches
    Margherita Ratti, Andrea Lampis, Jens Claus Hahne, Rodolfo Passalacqua, Nicola Valeri · 2018 · Cellular and Molecular Life Sciences
  91. Cancer Genome Evolutionary Trajectories in Metastasis
    Nicolai J. Birkbak, Nicholas McGranahan · 2020 · Cancer Cell
  92. KEAP1-driven co-mutations in lung adenocarcinoma unresponsive to immunotherapy despite high tumor mutational burden
    Daniele Marinelli, Marco Mazzotta, Stefano Scalera, Irene Terrenato, Francesca Sperati, L. D'Ambrosio, Matteo Pallocca, Giacomo Corleone, Eriseld Krasniqi, Laura Pizzuti et al. · 2020 · Annals of Oncology
  93. The mutational landscape of mucosal melanoma
    Kelsey W. Nassar, Aik Choon Tan · 2019 · Seminars in Cancer Biology
  94. Structural underpinnings of oestrogen receptor mutations in endocrine therapy resistance
    John A. Katzenellenbogen, Christopher G. Mayne, Benita S. Katzenellenbogen, Geoffrey L. Greene, Sarat Chandarlapaty · 2018 · Nature reviews. Cancer
  95. Resistance to TRK inhibition mediated by convergent MAPK pathway activation
    Emiliano Cocco, Alison M. Schram, Amanda R. Kulick, Sandra Misale, Helen H. Won, Rona D. Yaeger, Pedram Razavi, Ryan N. Ptashkin, Jaclyn Frances Hechtman, Eneda Toska et al. · 2019 · Nature Medicine
  96. TMB or not TMB as a biomarker: That is the question
    Alfredo Addeo, Alex Friedlaender, Giuseppe Luigi Banna, Glen J. Weiss · 2021 · Critical Reviews in Oncology/Hematology
  97. Prevalence of Clonal Hematopoiesis Mutations in Tumor-Only Clinical Genomic Profiling of Solid Tumors
    Ryan N. Ptashkin, Diana L. Mandelker, Catherine Callaghan Coombs, Kelly L. Bolton, Zarina Yelskaya, David Michael Hyman, David B. Solit, Jose M Baselga, Maria E. Arcila, Marc Ladanyi et al. · 2018 · JAMA Oncology
  98. Clinical cancer genomic profiling by three-platform sequencing of whole genome, whole exome and transcriptome
    Michael Rusch, Joy Nakitandwe, Sheila A. Shurtleff, Scott Newman, Zhaojie Zhang, Michael N. Edmonson, Matthew D. Parker, Yuannian Jiao, Xiaotu Ma, Yanling Liu et al. · 2018 · Nature Communications
  99. Application of Next Generation Sequencing in Laboratory Medicine
    Yiming Zhong, Feng Xu, Jinhua Wu, Jeffrey A. Schubert, Marilyn M. Li · 2020 · Annals of Laboratory Medicine
  100. Precision medicine in non-small cell lung cancer: Current applications and future directions
    Soo‐Ryum Yang, Anne Maria Schultheis, Helena Alexandra Yu, Diana L. Mandelker, Marc Ladanyi, Reinhard Büttner · 2020 · Seminars in Cancer Biology